["Treatment of lung cancer with immune checkpoints inhibitors"]

"Treatment of lung cancer with immune checkpoints inhibitors .Immunotherapy has considerably changed the treatment of lung cancer. Anti-PD-1 or anti-PD-L1, either as monotherapy or in combination with chemotherapy, are now the cornerstone of the treatment of metastatic non-small cell lung cancer and enable some patients to achieve prolonged survival, sometimes without evidence of residual disease. Durvalumab has improved the survival of patients after treatment with chemo-radiotherapy for locally advanced NSCLC. The contribution of anti-PD(L)-1 in combination with chemotherapy is more modest in small cell cancers, although for the first time it has improved survival in extensive stage of the disease. The next step will be to integrate checkpoint inhibitors into the treatment of earlier forms of the disease."